Thesis

147 20. Bakker ALM, Mathijssen H, Huitema MP, et al. Holter monitoring and cardiac biomarkers in screening for cardiac sarcoidosis. Lung. 2025;203(1). doi:10.1007/s00408-024-00772-5 21. Flotats A, Carrió I, Agostini D, et al. Proposal for standardization of 123Imetaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37(9):1802-1812. doi:10.1007/s00259-010-1491-4 22. Chirumamilla A, Travin MI. Cardiac applications of 123I-MIBG imaging. Semin Nucl Med. 2011;41(5):374-387. doi:10.1053/j.semnuclmed.2011.04.001 23. Freeman R. Assessment of cardiovascular autonomic function. Clin Neurophysiol. 2006;117(4):716-730. doi:10.1016/j.clinph.2005.09.027 24. Mathijssen H, Tjoeng TWH, Keijsers RGM, et al. The usefulness of repeated CMR and FDG PET/CT in the diagnosis of patients with initial possible cardiac sarcoidosis. EJNMMI Res. 2021;11(1). doi:10.1186/s13550-021-00870-y 25. Gimelli A, Liga R, Agostini D, et al. The role of myocardial innervation imaging in different clinical scenarios: an expert document of the European Association of Cardiovascular Imaging and Cardiovascular Committee of the European Association of Nuclear Medicine. Eur Heart J Cardiovasc Imaging. 2021;22(5):480-490. doi:10.1093/ehjci/jeab007 26. Tamaki N, Manabe O. Current status and perspectives of nuclear cardiology. Ann Nucl Med. 2024;38(1):20-30. doi:10.1007/s12149-023-01878-1 27. Misumi I, Kimura Y, Hokamura Y, et al. Scintigraphic detection of regional disruption of the adrenergic nervous system in sarcoid heart disease. Jpn Circ J. 1996;60(10):774-778. doi:10.1253/jcj.60.774 28. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 1998;5(6):579-590. doi:10.1016/s1071-3581(98)90112-x 9 153 9

RkJQdWJsaXNoZXIy MjY0ODMw